Abemaciclib mesylate(CAS: 1231930-82-7)

Abemaciclib mesylate is a chemotherapy agent used in the treatment of breast cancer. It is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor with the chemical formula C29H27N7O5S. It is commonly used in combination with endocrine therapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, particularly in those who have previously received endocrine therapy.

Abemaciclib mesylate is primarily used in the treatment of breast cancer. Specifically, it is used in combination with endocrine therapy to treat advanced or metastatic breast cancer in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative tumors, especially those who have previously received endocrine therapy.

Abemaciclib mesylate is generally considered safe when used as directed. However, it can cause side effects such as diarrhea, neutropenia, and fatigue. Patients should follow their healthcare provider's instructions and report any adverse reactions promptly. Appropriate precautionary measures, including regular blood monitoring, should be taken to ensure patient safety.

Abemaciclib mesylate should be stored at room temperature (15-30°C) and protected from light. It should be kept in a tightly sealed container to prevent moisture and light exposure. Storage conditions should be monitored to ensure stability and effectiveness of the drug. Avoiding extremes of temperature and humidity is crucial to maintain the integrity of the compound.